Login to Your Account

Avexis shakes up SMA space with pivotal trial plan

By Marie Powers
News Editor

Wednesday, November 2, 2016

Avexis Inc. is preparing for a David-and-Goliath showdown with Biogen Inc. and its partner, Ionis Pharmaceuticals Inc., after the FDA green-lighted the design of a pivotal trial for AVXS-101 in infants and children with SMA type 1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription